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PURPOSE. To evaluate the depth and pattern of retinal hemorrhage in acute central retinal
vein occlusion (CRVO) and to correlate these with visual and anatomic outcomes.
METHODS. Retinal hemorrhages were evaluated with color fundus photography and fluo-
rescein angiography at baseline and follow-up. Snellen visual acuity (VA), central foveal
thickness (CFT), extent of retinal ischemia, and development of neovascularization were
analyzed.
RESULTS. 108 eyes from 108 patients were evaluated. Mean age was 63.6 ± 16.1 years
with a predilection for the right eye (73.1%). Average follow-up was 17.2 ± 19.2 months.
Mean VA at baseline was 20/126 and 20/80 at final follow-up. Baseline (P = 0.005) and
final VA (P = 0.02) in eyes with perivascular nerve fiber layer (NFL) hemorrhages were
significantly worse than in eyes with deep hemorrhages alone. Baseline CFT was greater
in the group with perivascular hemorrhages (826 ± 394 μm) compared to the group with
deep hemorrhages alone (455 ± 273 μm, P < 0.001). The 10 disc areas of retinal ischemia
was more common in patients with perivascular (80.0%) and peripapillary (31.3%) versus
deep hemorrhages alone (16.1%, P < 0.001). Neovascularization of the iris was more
common, although this differrence was not significant, in the groups with peripapillary
(14.3%) and perivascular (2.0%) NFL versus deep hemorrhages alone (0.0%).
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CONCLUSIONS. NFL retinal hemorrhages at baseline correlate with more severe forms of
CRVO, with greater macular edema, poorer visual outcomes, and greater risk of ischemia
and neovascularization. This may be related to the organization of the retinal capil-
lary plexus. The depth and pattern of distribution of retinal hemorrhages in CRVO may
provide an easily identifiable early biomarker of CRVO prognosis.
Keywords: central retinal vein occlusion, nerve fiber layer hemorrhages, ischemia,
neovascularization
Decades of research have been devoted to the iden-tification of prognostic biomarkers that can predict
central retinal vein occlusion (CRVO) visual outcomes and
secondary complications. Initial studies identified poor base-
line visual acuity, visual field, relative afferent pupillary
defects, cotton wool spots and density of retinal hemor-
rhage as factors that portended a worse visual prognosis in
eyes with CRVO.1 The Central Vein Occlusion Study (CVOS)
and other studies confirmed that baseline vision and conflu-
ent retinal hemorrhage, in addition to other factors such as
afferent pupillary defect, correlated with worse outcomes
including a greater risk of neovascular glaucoma.2–5 The best
way to assess CRVO outcomes may be to quantify the area
of ischemia or non-perfusion with fluorescein angiography
but interpretation was originally defined in the pre-widefield
imaging era, can be limited by the presence of blood, and
requires invasive dye injection.6,7
Advanced retinal imaging has provided greater insight
into the evaluation of retinal vascular disease. Mild forms
of CRVO may present with only middle retinal ischemia,
not detectable with dye-based angiography, and identified as
bands of hyperreflectivity in the inner nuclear layer referred
to as paracentral acute middle maculopathy (PAMM).8–12
These PAMM lesions may follow a perivenular distribution,
best detected with en face optical coherence tomography
(OCT), which may represent the mildest form of ischemic
injury in CRVO13,14 and the initial manifestation of the
process recently referred to as the ischemic cascade.15
The progression of ischemic damage from the middle to
the inner retinal layers in CRVO may share a parallel path-
way with hemorrhage. Blood can be isolated in the Henle’s
fiber layer (HFL) as a result of systemic or local etiologies
of elevated venous pressure including retinal vein occlu-
sion.16–18,39 Several studies have suggested that the inter-
mediate and deep retinal capillary plexuses may represent
the major level of venous outflow and it has therefore been
proposed that ischemia and hemorrhage may first develop
in the deeper layers of the retina.14,15,19,20 With more severe
venous occlusion, inner retinal ischemia and inner retinal
hemorrhage may occur more frequently.15
We propose that the depth and pattern of distribution
of retinal hemorrhages at presentation in eyes with CRVO
may provide easily identifiable biomarkers that can predict
visual and anatomical outcomes. Therefore, the purpose of
this study was to correlate the level and location of retinal
hemorrhage in eyes with CRVO with visual and anatomical
parameters at baseline and follow-up.
METHODS
This retrospective observational study was approved by the
Institutional Review Board at the University of California,
Los Angeles and adhered to the Health Insurance Porta-
bility and Accountability Act (HIPAA) and was performed
in accordance with the Declaration of Helsinki. Patients
were evaluated at multiple international tertiary care centers
(with which the co-authors are affiliated) between January
1, 2010, and September 30, 2019. Co-authors determined
respective IRB requirements and provided de-identified clin-
ical datasets and imaging.
Inclusion criteria were comprised of a clinical diagno-
sis of acute treatment naïve CRVO rendered by the refer-
ring retinal specialist based on clinical examination, spectral
domain-optical coherence tomography (SD-OCT), and fluo-
rescein angiography (FA). Patients were included if they had
a minimum of three months of follow-up with baseline color
fundus photography, FA, and SD-OCT volume scans through
the central macular region. Acute CRVO was confirmed
based on color fundus photography and FA showing the
presence of four quadrants of retinal hemorrhages with reti-
nal venous dilation, congestion, and tortuosity, and delayed
arterio-venous dye transit (at least 20 seconds) within
one month of symptoms onset. Eyes were excluded if they
had a concomitant central retinal artery occlusion, evidence
of a branch or hemi-central retinal vein occlusion, moder-
ate or severe non-proliferative diabetic retinopathy, prolif-
erative diabetic retinopathy, or significant vitreous hemor-
rhage preventing fundus photography.
All patients underwent comprehensive ophthalmic
assessment including slit-lamp biomicroscopy, indirect
ophthalmoscopy, and multimodal retinal imaging. Color
fundus photography was performed using a conventional
fundus photography camera (Carl Zeiss Meditec, Dublin
California, USA; or Topcon, Tokyo, Japan) or an ultra-
widefield system (Optos Panoramic 200MA, California, USA;
Optos PLC, Dunfermline, Scotland, UK). SD-OCT scans
(Spectralis HRA, Heidelberg Engineering; Cirrus HD-OCT
4000, V.5.0, Carl Zeiss Meditec) and fluorescein angiogra-
phy (Topcon TRC-50; Spectralis HRA, Heidelberg Engineer-
ing; Carl Zeiss Meditec; Optos PLC) were captured on all
patients. All OCT images were exported to ImageJ (Version
2.0.0-rc-69/1.52p) and scaled according to the built-in scale
ledger. Central foveal point thickness (CFT) was manually
measured at the central fovea from the internal to the exter-
nal limiting membrane in order to minimize variability of
thickness measurements between OCT machines. Additional
clinical data collected for each patient included age, sex,
past medical history, systemic medications, and treatment
history (i.e. details regarding therapy with intravitreal anti–
vascular endothelial growth factor (VEGF) injections, intrav-
itreal steroids, or panretinal photocoagulation (PRP) laser).
Therapeutic choice and frequency of administration were
determined by the treating provider. Treatment indications
were consistent across institution. PRP was performed to
target peripheral retinal ischemia, anti-VEGF injections were
administered for the treatment of cystoid macular edema
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(CME) or subretinal fluid (SRF) or neovascularization of the
iris (NVI) or neovascular glaucoma (NVG), and intravitreal
steroids were administered for the treatment of macular
edema.
Retinal layer depth and location of hemorrhage were
determined based on color fundus photography and FA anal-
ysis at presentation. Nerve fiber layer (NFL) hemorrhages
were defined as hemorrhages that displayed a flame shape
and/or radiated within the NFL and/or obscured larger reti-
nal vessels. Hemorrhages were considered deep if they were
noted beneath the superficial retinal vasculature with a
round shape. Presence of more than two non-contiguous
hemorrhages at a given level in the designated region was
considered abnormal. Regional localization of the hemor-
rhages within the peripapillary and perivascular regions was
defined as follows. The peripapillary region was defined
as a 1-disc diameter area from the optic disc margin. The
perivascular region of hemorrhages referred to hemorrhages
radiating along the NFL radiations along the major tempo-
ral arcades. Specifically, we identified these hemorrhages
approximately 1.5 mm–4.5 mm from the optic disc. The
temporal border was assessed clinically by placing a vertical
line transecting the fovea. Analysis was performed compar-
ing these three groups of increasing severity of hemor-
rhage (from least to greatest): deep hemorrhages alone, deep
hemorrhages and peripapillary NFL hemorrhages (peripap-
illary group), and deep hemorrhages and peripapillary and
perivascular NFL hemorrhages (perivascular group).
Presence of neovascularization of the iris (NVI), neovas-
cular glaucoma (NVG), and vitreous hemorrhage (VH) were
determined by the treating provider. Hemorrhage location
and extent of ischemia was graded by the first author (AA)
based on color and FA images submitted by the referring
coauthors and based on the widest view provided. A second
grader masked to all clinical data was asked to determine
location of hemorrhage and presence/absence of ischemia
(AH, JS, FG, DW, CG). Discrepancies were determined by
a senior arbiter (DS). Ischemia was defined as greater than
10 disc areas (DA) of non-perfusion present on fluorescein
angiography on the widest available view provided, includ-
ing outside the seven standard fields.4,21,22 In eyes with
multiple FAs, the final FA was used to determine the extent
of ischemia. Eyes with confluent hemorrhages that obscured
assessment of ischemia or without widefield imaging were
eliminated from the ischemia analysis. Presence or absence
of CME or SRF was determined based on evaluation of the
sub-foveal SD-OCT B-scan.
Statistical analyses were performed using R version
3.5.0 (www.r-project.org). Demographic parameters were
reported as mean and standard deviations or numerical
counts with percentages. Analysis of ischemic outcomes by
hemorrhage level and location was presented as numer-
ical counts and percentages. Snellen visual acuities were
converted to logMAR for statistical analysis. Vision was
reported as mean and median logMAR vision with Snellen
conversion. Central foveal thickness was reported as mean
and standard deviations. Comparison of continuous vari-
ables was performed with analysis of variance with post-
hoc Tukey HSD between the three groups. Pearson’s corre-
lation was performed between CFT and baseline or final
visual acuity. Cohen’s Kappa statistic was calculated for inter-
grader reliability. Bonferroni correction was implemented
when post-hoc Chi-squared tests were performed between
three groups. In these cases P < 0.016 (0.05/3). Otherwise,
P values < 0.05 were considered significant.
RESULTS
Demographics and Treatment History of the
Entire Cohort
A total of 108 eyes with CRVO from 108 patients were
included and analyzed. Contribution of cases by each insti-
tution is summarized in Supplementary Table S1. At base-
line, 37 eyes displayed deep retinal hemorrhages only, 21
eyes displayed deep retinal hemorrhages plus peripapillary
NFL (nerve fiber layer) hemorrhages, and 50 eyes displayed
deep hemorrhages plus peripapillary and perivascular NFL
hemorrhages. An example of a case of CRVO with deep
hemorrhages alone (Fig. 1), peripapillary NFL hemorrhages
(Fig. 2), and perivascular NFL hemorrhages (Fig. 3) are
shown. None of the patients presented with peripapillary or
perivascular hemorrhages alone. Cohen’s κ for inter-grader
reliability was 0.76 (0.63–0.88) between graders for distribu-
tion of hemorrhage groups.
Average patient age in the total cohort was 63.6 ± 16.1
years of age and predominantly male (66/108 or 61.1%) with
a predilection for the right eye 79/108 (73.1%) (Table 1).
Average follow-up period was 17.2 ± 19.2 months (range
2.8 to 105.3 months). In total, 87.0% (94/108) of the patients
received at least one anti-VEGF injection (mean 8.5 ± 9.3
injections, range 1–50), 3.7% (4/108) received intravitreal
steroids, and 6.5% (7/108) received PRP laser therapy. No
patients received intravitreal steroids as first line therapy.
Of the four patients with intravitreal steroids, one received
three Ozurdex injections, one received five Ozurdex injec-
tions, and the other two received one Ozurdex and one
Kenalog injection during follow-up. Eyes with only deep reti-
nal hemorrhages (26/37, 70.3%) were significantly less likely
to have received anti-VEGF injections compared to eyes
with peripapillary (21/21, 100.0%, P = 0.006) and perivas-
cular NFL hemorrhages (47/50, 94.0%, P = 0.003). No differ-
ence in anti-VEGF frequency existed between the perivascu-
lar and peripapillary hemorrhage groups (P = 0.25). When
comparing the rate of anti-VEGF injection over the entire
follow-up, patients with only deep hemorrhages underwent
0.5 ± 0.3 injections per month, patients with deep retinal
hemorrhages plus peripapillary NFL hemorrhages received
0.9 ± 0.9 injections per month, and patients with deep reti-
nal hemorrhages plus peripapillary and perivascular NFL
hemorrhages underwent 0.8 ± 0.9 injections per month
(P = 0.20).
Correlation Between Baseline NFL Hemorrhage
Pattern and Baseline and Final Visual Acuity
Visual outcomes were compared in eyes with hemorrhages
involving the NFL versus eyes without hemorrhage in the
NFL at baseline presentation (Table 2). Baseline visual acuity
in the group with deep retinal hemorrhages alone was
20/100, and in the group with peripapillary NFL hemor-
rhages it was 20/63, and in the group with perivascular NFL
hemorrhages it was 20/200 (P < 0.003). Post-hoc Tukey’s
HSD analysis showed that the significant difference in base-
line visual acuity was between the peripapillary and perivas-
cular (P = 0.002) groups and the deep and perivascular
groups (P = 0.005) but not between the deep and peripapil-
lary hemorrhage group (P = 0.78). However, at final follow-
up there was a graded effect in average visual acuity. Eyes
with deep hemorrhages alone improved to 20/40, eyes with
peripapillary NFL hemorrhages stabilized at 20/80, and eyes
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FIGURE 1. Case 1. Acute CRVO with deep retinal hemorrhages only. Baseline color fundus photograph (A) and fluorescein angiogram
(B) show deep retinal hemorrhages in the macula (arrowheads) and no evidence of NFL hemorrhages and no fluid with OCT (C). Follow-up
at 3 months demonstrates progressive deep retinal hemorrhages (arrowheads) on color fundus photograph (D) and fluorescein angiogram
(E), but still no evidence of NFL hemorrhages. One hemorrhage located in the macula can be identified as deep on OCT (F, arrow). Mild
cystic changes were noted on the OCT (F) but no anti-VEGF injection was given. Vision was 20/40 at baseline and last follow-up.
FIGURE 2. Case 2. Acute CRVO with deep retinal hemorrhages plus peripapillary NFL hemorrhages. Baseline vision was 20/50.
Baseline fundus photograph (A) shows superficial NFL hemorrhages in the peripapillary region (arrows) and deep retinal hemorrhages in
the macula, which are confirmed on fluorescein angiography (B). At 9 months, follow-up widefield fundus photograph shows persistent
deep hemorrhages (C) and follow-up widefield fluorescein angiography illustrates >10 disc areas of nonperfusion, most notably in the
temporal retina (D). Baseline SD-OCT (E) shows cystoid macular edema and shallow central subretinal fluid. Follow-up SD-OCT (F) shows
persistent CME and SRF despite six bevacizumab injections. Vision worsened to 20/125.
with perivascular NFL hemorrhages demonstrated the lowest
VA at 20/100 (P = 0.03). Statistical significance occurred
between the deep and perivascular hemorrhage group (P =
0.02); differences between the peripapillary versus perivas-
cular (P = 0.49) and deep versus peripapillary (P = 0.52)
groups were not significant.
Baseline Hemorrhage Level Correlation with
Central Foveal Thickness (CFT) and Fluid Status
Baseline CFT was significantly less in the group with deep
hemorrhages alone (455 μm ± 273 μm, P < 0.001) and in
the group with peripapillary hemorrhages (534 ± 270 μm,
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FIGURE 3. Case 3. Acute CRVO with deep retinal hemorrhages plus peripapillary NFL and perivascular NFL hemorrhages.Widefield
fundus photograph at baseline presentation (A) shows flame-shaped NFL hemorrhages in the peripapillary and perivascular regions (arrows)
that nearly resolve at the 5-month follow-up visit (D). Widefield fluorescein angiography at baseline (B) demonstrates that the hemorrhages
are superficial in a peripapillary and perivascular NFL distribution. Vision at presentation was 20/800. At the 5-month follow-up visit, vision
improved to 20/200 but significant (greater than 10 disc areas) diffuse retinal ischemia was noted (E). SD-OCT shows significant central
cystoid macular edema at baseline presentation (C) that was much improved at the 5-month follow-up visit (F) after six aflibercept injections.
TABLE 1. Demographics and Treatment History of Study Population
Total (N = 108)
Deep
Hemorrhage
Only (N = 37)
Deep +
Peripapillary
NFL (N = 21)
Deep + Peripapillary
NFL + Perivascular
NFL (N = 50) P Value
Age (yr, average ± SD) 63.6 ± 16.1 61.5 ± 18.3 68.0 ± 13.3 63.4 ± 15.4 0.35
Sex
Male, n (%) 66 (61.1) 18 (48.6) 15 (71.4) 33 (66.0) 0.15
Female, n (%) 42 (38.9) 19 (51.4) 6 (28.6) 17 (34.0)
Eye
OD, n (%) 79 (73.1) 31 (83.8) 15 (71.4) 33 (66.0) 0.18
OS, n (%) 29 (26.9) 6 (16.2) 6 (28.6) 17 (34.0)
Follow-up (mo, average ± SD) 17.2 ± 19.2 20.4 ± 23.7 20.0 ± 20.0 13.6 ± 14.4 0.19
Received anti-VEGF treatment, n (%) 94 (87.0) 26 (70.3) 21 (100.0) 47 (94.0) <0.001
Injections/total follow-up
(injections/mo, average ± SD)
0.7 ± 0.8 0.5 ± 0.3 0.9 ± 0.9 0.8 ± 09 0.20
Intravitreal steroids, n (%) 4 (3.7) 0 (0.0) 2 (9.5) 2 (4.0) 0.21
Panretinal photocoagulation, n (%) 7 (6.5) 1 (2.7) 1 (4.8) 5 (10.0) 0.37
NFL, nerve fiber layer; SD, standard deviation; VEGF, vascular endothelial growth factor.
P = 0.002) compared to the group with perivascular NFL
hemorrhages (826 ± 394 μm). No difference was noted
between the groups with deep versus peripapillary hemor-
rhages (P = 0.72) (Table 2). Illustrations of the correlation
of CME and CFT are shown in Figures 1C (absent CME in a
CRVO case with only deep hemorrhages), 2E (baseline CFT
of 774 in a CRVO case with peripapillary NFL hemorrhage)
and 3C (baseline CFT of 912 in a CRVO case with perivas-
cular NFL hemorrhages). There was a correlation between
baseline CFT and baseline visual acuity (r = 0.45, P <
0.001) and final visual acuity (r = 0.24, p = 0.01) across all
groups.
Cystoid macular edema was present in 64.9% (24/37)
of CRVO eyes with deep retinal hemorrhages alone, 81.0%
(17/21) of eyes with deep retinal hemorrhages and peripap-
illary NFL hemorrhages, and 86.0% (43/50) of eyes with deep
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NFL (N = 21)
Deep + Peripapillary
NFL + Perivascular
NFL (N = 50) P Value
Baseline vision (logMAR, average ± SD,
median, Snellen equivalent)
0.8 ± 0.5, 0.8
(20/126)
0.7 ± 0.5, 0.7
(20/100)
0.6 ± 0.7, 0.5
(20/63)
1.0 ± 0.5, 1.0
(20/200)
0.003
Final vision (logMAR, average ± SD, median,
Snellen equivalent)
0.7 ± 0.7, 0.6
(20/80)
0.5 ± 0.5, 0.3
(20/40)
0.7 ± 0.5, 0.6
(20/80)
0.9 ± 0.8, 0.7
(20/100)
0.03
Baseline central foveal thickness
(μm, average ± SD, median)
640 ± 358 455 ± 273 534 ± 270 826 ± 394 <0.001
NFL, nerve fiber layer; SD, standard deviation.
TABLE 3. Anatomical Outcomes Associated with Hemorrhage Location
Total (N = 108)
Deep
Hemorrhage
Only (N = 37)
Deep +
Peripapillary
NFL (N = 21)
Deep + Peripapillary
NFL + Perivascular
NFL (N = 50) P Value
Ischemia >10 DA of nonperfusion, n (%)* 38 (46.3) 5 (16.1) 5 (31.3) 28 (80.0) <0.001
No ischemia <10 DA of nonperfusion, n (%)* 44 (53.7) 26 (83.9) 11 (68.7) 7 (20.0)
NVI, n (%) 4 (3.7) 0 (0.0) 3 (14.3) 1 (2.0) 0.01
NVG, n (%) 1 (0.9) 0 (0.0) 0 (0.0) 1 (2.0) –
PRH, n (%) 11 (10.2) 3 (8.1) 1 (4.8) 7 (14.0) 0.44
VH, n (%) 4 (3.7) 2 (5.4) 1 (4.8) 1 (2.0) 0.68
CME, n (%) 84 (77.8) 24 (64.9) 17 (81.0) 43 (86.0) 0.03
SRF, n (%) 42 (38.9) 11 (29.7) 11 (52.4) 20 (40.0) 0.23
DA, disc areas; NFL, nerve fiber layer; NVI, neovascularization of the iris; NVG, neovascular glaucoma; PRH, preretinal hemorrhage; VH,
vitreous hemorrhage; CME, cystoid macular edema; SRF, subretinal fluid. *Due to a lack of widefield FA or blockage from hemorrhage, eyes
in the total (N=82), deep hemorrhage only (N=31), deep + peripapillary NFL (n=16), deep + peripapillary NFL + perivascular NFL (n=35)
groups are reduced. Percentages and statistical tests reflect these reduced number.
retinal hemorrhages and peripapillary and perivascular NFL
hemorrhages (P = 0.03, Table 3). Post-hoc χ2 tests demon-
strated that these differences were primarily between the
groups with deep and perivascular NFL hemorrhages that
did not reach significance with the conservative Bonferroni
correction (P = 0.02). Subretinal fluid was present in 29.7%
(11/37) of eyes with deep retinal hemorrhages alone, 52.4
% (11/21) of eyes with peripapillary NFL hemorrhages, and
40.0% (20/50) of eyes with perivascular NFL hemorrhages
(P = 0.23) (Table 3).
Baseline Hemorrhage Level Correlation with
Ischemic Outcomes
In total, 26 of the 108 eyes were excluded only as pertains
to the ischemic evaluation due to lack of widefield imaging
or blockage from hemorrhage. Specifically this occurred in 6
eyes in the deep (n=31), 5 eyes in the peripapillary (n=16),
and 15 eyes in the perivascular (n=35) groups. In total,
38 (46.3%) eyes displayed >10 disc areas of ischemia (i.e.,
ischemic CRVO), whereas 44 (53.7%) eyes were considered
nonischemic CRVO. Ischemic CRVO was identified in 16.1%
(5/31) of eyes with deep hemorrhages alone, 31.3% (5/16) of
eyes with peripapillary NFL hemorrhages, and 80.0% (28/35)
of eyes with perivascular NFL hemorrhages (P < 0.001)
(Table 3). Please see Figures 2D, 3B, and 3E for case
examples. Post-hoc χ2 tests illustrated continued statistical
significance between the peripapillary versus perivascular
(P = 0.001) and deep versus perivascular (P < 0.001) groups
but not between the deep versus peripapillary groups
(P = 0.23). In the 39 eyes with less than 6-month follow-
up, 0/13 (0.0%) in the deep hemorrhage alone group, 1/5
(20.0%) in the peripapillary group, and 14/21 (66.7%) in the
perivascular group illustrated evidence of ischemic CRVO.
Of those eyes with NVI (a total of four of 108 eyes), three
were in the peripapillary NFL hemorrhage group and one
was in the perivascular NFL hemorrhage group. Only one
eye in the entire cohort developed NVG, and this eye showed
perivascular NFL hemorrhages. Eyes with preretinal hemor-
rhages were less likely to show deep hemorrhages alone
(3/37, 8.1%) versus the group with perivascular NFL hemor-
rhages (7/50, 14.0%), but this was not statistically significant
(P = 0.44).
DISCUSSION
This study evaluated the depth and pattern of distribution of
retinal hemorrhages at presentation as a potential biomarker
for visual and anatomic outcomes in patients with acute
CRVO. Eyes with baseline retinal hemorrhages in a perivas-
cular NFL distribution i.e. radial extension of the hemor-
rhages along the temporal vascular arcades exhibited signif-
icantly worse baseline and final visual acuities, a greater
prevalence and severity of cystoid macular edema, a greater
frequency of ischemic CRVO (versus nonischemic CRVO),
and a greater rate of anti-VEGF injection therapy.
Other known biomarkers of ischemic CRVO have been
described and include baseline visual acuity, relative affer-
ent pupillary defect, cotton wool spots and extent of retinal
hemorrhages.1,2,4 From the CVOS, nonperfusion of greater
than 10 disc areas with FA was a key risk factor for neovas-
cularization.4,22 In fact, Nicholson et al.5 demonstrated that
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FIGURE 4. Diagram illustrating proposed cascade or progression of increased venous pressure leading to the distribution of retinal
hemorrhages. Hemorrhages are first noted at the level of the deep retinal capillary plexus (DCP), the major level of venous outflow, in the
posterior pole and periphery.8,9,11,14,19,20 Pressure will subsequently be transmitted in more severe forms of CRVO through the intermediate
capillary plexus (IVP), the superficial capillary plexus (SCP) and ultimately to the RPC.28,33,38 Therefore, hemorrhages within the RPC NFL
may indicate a more severe form of CRVO. Reprinted with permission from Fouquet S, Vacca O, Sennlaub F, Paques M. The 3D retinal
capillary circulation in pigs reveals a predominant serial organization. Invest Ophthalmol Vis Sci. 2017;58:5754–5763. © 2017 The Authors.
Published by the Association for Research in Vision and Ophthalmology (ARVO).
ischemia or nonperfusion area of 75 to 150 disc areas
was associated with an 80% rate of neovascularization. Tsui
et al.23 confirmed that eyes with a nonperfused area or
ischemic index of 45% of the total retina area were at a
significantly greater risk of neovascularization. Hayreh et
al.2 evaluated the pattern of retinal hemorrhages in acute
CRVO and found that 92% of patients with ischemic CRVO
displayed peripapillary hemorrhages versus 71% of eyes
with nonischemic CRVO at baseline. In addition, 47% of
the eyes with ischemic CRVO versus 16% with nonischemic
CRVO displayed severe hemorrhages in the peripapillary
area. Although the Hayreh study did not use 10 disc areas
of nonperfusion to define an ischemic CRVO and did not
evaluate or identify depth of hemorrhage as a risk factor,
his findings are consistent with the results of our study
suggesting that perivascular NFL hemorrhages portend a
worse anatomic and visual outcome. However, it should be
noted that the definition of 10 DA as a critical margin for
ischemia differs from that which was originally described
in CVOS, as this was defined in relationship to the stan-
dard seven fields.4,22 Furthermore, 10 DA of ischemia was
arbitrarily determined and not considered a step-up in
risk.
The development of retinal hemorrhages and ischemia
may have a common pathophysiology in eyes with CRVO. A
thrombus in the central retinal vein, most commonly located
posterior to the lamina cribosa, may initiate a cascade of
events including increased hydrostatic pressure within the
retinal venous system that is transmitted from the venous
pole to the terminal arterioles.24,25 Middle retinal infarc-
tion at the level of the inner nuclear layer, identified as
PAMM on SD-OCT and perivenular PAMM with en face OCT,
may be the first manifestation of ischemic injury in eyes
with CRVO.8–12 In more severe cases, ischemia progresses
towards the arterial pole leading to inner retinal ischemia.
This is detected on SD-OCT as hyperreflectivity of the
inner and middle retina. This has been termed the ischemic
cascade.15 The development of retinal hemorrhages may
show a similar sequence of progression.
In patients with elevated retinal venous pressure due to
local and systemic etiologies, retinal hemorrhages may be
identified only in the Henle fiber layer.16–18,39 This suggests
that the intermediate and deep retinal capillary plexus may
be the major site of venous outflow and may be at great-
est risk of ischemia and hemorrhage.19,20 In more severe
cases, ischemia and hemorrhage may track superficially into
the inner retina, and as suggested by this study, extend into
the radial peripapillary capillary plexi (RPC) within the NFL.
This is mainly in an area radiating away from the disc where
the NFL is thickest and the RPC is present; more peripheral,
the RPC is absent and only deep retinal hemorrhages are
seen.26,27
The organization of the retinal capillary plexus has been
extensively studied but the exact arrangement, specifically
the nature of the venous drainage, has not been clearly eluci-
dated.20 Fouquet et al.28 have illustrated a serial arrange-
ment of the retinal microvasculature in which the RPC drains
directly into the DCP and subsequently empties into a post-
capillary venule in pigs (Fig. 4). This has been confirmed in
other mammals and in humans.20,29–32 More recent human
ex vivo studies, however, contradict this pattern of venous
drainage.33 Our findings suggest that in eyes with CRVO,
the ICP and DCP (closest to the draining venules) may be
at greatest risk of injury from increased hydrostatic pressure
while the SCP and the RPC may be more resistant. Thus
hemorrhage and ischemia will develop first in the region of
the ICP and DCP and with more severe occlusion, hemor-
rhage and ischemia will be evident in the superficial capil-
lary plexus and ultimately the RPC NFL.8–12,34 This pathway
may explain the salient finding of this study, which identified
RPC NFL hemorrhages, particularly along the radial perivas-
cular extensions, as a biomarker of a more severe phenotype
of CRVO with worse visual outcomes and increased retinal
ischemia and cystoid macular edema.
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This pathway may also explain why patients with
more severe CRVO display more extensive retinal hemor-
rhages. The extent of hemorrhage is a commonly accepted
biomarker for ischemic CRVO but its identification lacks the
mechanistic understanding this paper provides.2,22 Further,
it is important to note that in this study NFL hemorrhage
correlated not only with greater ischemia but also with
worse visual outcomes, greater central macular thickness,
and greater prevalence and severity of CME and increased
rate of treatment with anti-VEGF. This would indicate that
NFL hemorrhages correspond to outcomes beyond ischemia
that strengthen its independence from extent of hemor-
rhages.
An unexpected finding of our study is the predilection
of acute CRVO in the right eye across the entire cohort
of patients. We speculate that this may be due to the
unique anatomy of the right internal jugular vein which
connects directly with the SVC or superior vena cava (the
left internal jugular vein is separated from the SVC by
the innominate vein) leading to greater venous pressures
on the right side. As the right atrium fills during diastole
against a closed tricuspid valve, the pressure increases due
to increased blood volume. This pressure is likely exac-
erbated in patients with chronic hypertension who have
hypertrophic myocardium, stiffened vessels, or sclerotic or
incompetent tricuspid valve. As a result, this increases retro-
grade pressure that can be transmitted to the superior
ophthalmic vein and potentially the central retinal vein. This
has been supported by studies that have demonstrated a
larger right than left internal jugular vein by ultrasound or
CT scan.35–37
Limitations of this study include the retrospective design,
the nonstandardized imaging protocols, and the variable
follow-up which prevented uniform analysis of all eyes.
As ischemia was considered within and outside the stan-
dard seven fields, bias may have been introduced as areas
of the peripheral retina may not have been appropriately
captured in all cases. The heterogenous follow-up made it
difficult to assess subtle changes in visual acuity and the rela-
tive impact of anti-VEGF therapy efficacy and its effect on
macular edema and neovascularization. The development of
neovascularization of the iris or neovascular glaucoma may
have been masked by anti-VEGF therapy given for coexistent
cystoid macular edema. Furthermore, the extent of ischemia
can change over time and can be masked by blockage
from hemorrhage on fluorescein angiography. Additional
systemic factors (e.g. anticoagulation, blood pressure) may
have influenced the extent and severity of hemorrhages and
may have also confounded our findings. Last, the study was
underpowered to statistically evaluate for trends that were
not significant, such as the number of injections performed
per month. Future prospective longitudinal studies with a
standardized imaging protocol and a natural history control
cohort will be necessary to formally validate the findings of
this study. However, this investigation may serve as a pilot
study to be further validated with larger prospective data
sets that include uniform multimodal retinal imaging.
In conclusion, we provide evidence that in CRVO patients,
eyes with retinal hemorrhages located in the RPC NFL,
specifically along the major vascular arcades, may represent
more severe forms of CRVO with worse visual outcomes,
increased cystoid macular edema, and greater risk of
ischemic complications. As such, perivascular NFL hemor-
rhage radiating along the vascular arcades may provide an
easily identifiable biomarker of ischemic CRVO at greater
risk for iris and angle neovascularization and with more
adverse visual and anatomical outcomes.
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